A study presented at the European Association for the Study of Diabetes Annual Meeting compared mazdutide, a GLP-1/glucagon dual agonist, with dulaglutide for adults with type 2 diabetes. Results showed that mazdutide led to greater decreases in HbA1c levels and body weight compared to dulaglutide. The study, funded by Innovent Biologics, enrolled 731 adults with type 2 diabetes, showing that mazdutide resulted in significant improvements in glycemic control, weight reductions, and cardiometabolic risk factors. However, participants reported more gastrointestinal adverse events with mazdutide, including diarrhea, nausea, and vomiting, compared to dulaglutide.
Source link
Mazdutide superior to dulaglutide for reducing HbA1c, body weight in type 2 diabetes
